EA5181
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable
Trial overview
| Disease | Lung cancer treatment and diagnosis |
| Topic | EA5181 |
| Description | Primary Objective:The primary objective of the trial is to determine whether concurrent MEDI4736 (durvalumab) with cytoxic chemo/radiation improves overall survival (OS) in addition to a standard therapy (chemotherapy and radiation followed by consolidative MEDI4736 (durvalumab)). Secondary objectives include estimation of progression-free survival, best objective response, incidence of local/distant progression, and toxicity.Patient Population:Patients with unresectable Stage 3 Non-small cell lung cancer. |
| Physicians | Dr. Alvaro A. MartinezMD, FACR, FABS, FASTRO Radiation Oncologist Works at 5 centers.Dr. Frank A. ViciniMD, FACR, FASTRO Radiation oncologist Works at 3 centers.Dr. Larry L. KestinMD, FACR Radiation Oncologist Works at 3 centers.Dr. Thomas BoikeMD Radiation Oncologist Works at 3 centers.Dr. Michael I. GhilezanMD, PhD Radiation Oncologist Works at 4 centers.Dr. John Vito AntonucciMD Radiation Oncologist Works at 4 centers. |